Acalabrutinib + Rabeprazole
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Infectious Disease
Conditions
Infectious Disease
Trial Timeline
Jul 20, 2020 → Aug 28, 2020
NCT ID
NCT04489797About Acalabrutinib + Rabeprazole
Acalabrutinib + Rabeprazole is a phase 1 stage product being developed by AstraZeneca for Infectious Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT04489797. Target conditions include Infectious Disease.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04489797 | Phase 1 | Completed |
Competing Products
20 competing products in Infectious Disease